News
AbbVie Pays $10.9 Billion Cash for Apogee Therapeutics at ~50% Premium
AbbVie is acquiring clinical-stage biotech Apogee Therapeutics for $135.11 per share in cash — a 49% premium — betting big on its anti-IL-13 antibody zumilokibart for atopic dermatitis and asthma. Apogee shares surged ~48% premarket Monday.